Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating

I initiate Palisade Bio with a speculative buy, citing its differentiated microbiome-activated PDE4 inhibitor, PALI-2108, targeting IBD. PALI-2108's phase 1 data show promising efficacy, mechanistic engagement, and improved tolerability versus systemic PDE4 inhibitors, supporting further development. PALI's $133M cash position provides 3–4 years of runway, mitigating near-term financing risk for advancing into pivotal phase 2 trials.